Status:
COMPLETED
Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19
Lead Sponsor:
Qiang Hu
Conditions:
Covid19
Lymphopenia
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
The mechanism of peripheral blood lymphocyte decline in COVID-19 patients is not yet clear. However, one theory demonstrated that in the whole progression of COVID-19, the extensive activation of poly...
Eligibility Criteria
Inclusion
- the patients diagnosed as the common or severe cases of COVID-19
- aged 18-85
- the absolute lymphocyte counts below the normal value (\<1.1-3.2×109/L)
Exclusion
- the patients who are diagnosed as critically ill cases or participating in other clinical trials
- women who are pregnant or lactating
- ALT/AST \> 5 times upper limit of normal (ULN), neutrophils counts \< 0.5×109/L, platelets counts\< 50×109/L
- patients diagnosed with rheumatoid immune-related diseases
- patients who take long-term oral anti-rejection drugs or immunomodulatory drugs
- hypersensitive reaction to nicotinamide or any auxiliary materials
- patients with active tuberculosis or combined with bacterial and fungal infections
- patients undergoing organ transplant
- patients with mental disorders.
Key Trial Info
Start Date :
March 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 2 2020
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04910230
Start Date
March 1 2020
End Date
April 2 2020
Last Update
November 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
General Hospital of Northern Theater Command
Shenyang, Liaoning, China, 110016